Cargando…

Current State and Principles of Basal Insulin Therapy in Type 2 Diabetes

Treatment with basal insulins is a fundamental part of management in many patients with type 2 diabetes mellitus. Multiple management schemes may be indicated in these individuals, for example, the use of oral antihyperglycemic agents with basal insulins (basal-supported oral therapy) or the combina...

Descripción completa

Detalles Bibliográficos
Autor principal: Vargas-Uricoechea, Hernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827224/
https://www.ncbi.nlm.nih.gov/pubmed/35211212
http://dx.doi.org/10.14740/jocmr4660
_version_ 1784647583428247552
author Vargas-Uricoechea, Hernando
author_facet Vargas-Uricoechea, Hernando
author_sort Vargas-Uricoechea, Hernando
collection PubMed
description Treatment with basal insulins is a fundamental part of management in many patients with type 2 diabetes mellitus. Multiple management schemes may be indicated in these individuals, for example, the use of oral antihyperglycemic agents with basal insulins (basal-supported oral therapy) or the combinations of basal insulins with glucagon-like peptide-1 receptor agonists; each of these strategies makes it easier to achieve glycemic control goals. A basic knowledge of the physiology, pharmacodynamic and pharmacokinetic aspects of the different basal insulins is essential to achieve treatment goals and compliance. This review addresses the principles of management with basal insulins.
format Online
Article
Text
id pubmed-8827224
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-88272242022-02-23 Current State and Principles of Basal Insulin Therapy in Type 2 Diabetes Vargas-Uricoechea, Hernando J Clin Med Res Review Treatment with basal insulins is a fundamental part of management in many patients with type 2 diabetes mellitus. Multiple management schemes may be indicated in these individuals, for example, the use of oral antihyperglycemic agents with basal insulins (basal-supported oral therapy) or the combinations of basal insulins with glucagon-like peptide-1 receptor agonists; each of these strategies makes it easier to achieve glycemic control goals. A basic knowledge of the physiology, pharmacodynamic and pharmacokinetic aspects of the different basal insulins is essential to achieve treatment goals and compliance. This review addresses the principles of management with basal insulins. Elmer Press 2022-01 2022-01-29 /pmc/articles/PMC8827224/ /pubmed/35211212 http://dx.doi.org/10.14740/jocmr4660 Text en Copyright 2022, Vargas-Uricoechea https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Vargas-Uricoechea, Hernando
Current State and Principles of Basal Insulin Therapy in Type 2 Diabetes
title Current State and Principles of Basal Insulin Therapy in Type 2 Diabetes
title_full Current State and Principles of Basal Insulin Therapy in Type 2 Diabetes
title_fullStr Current State and Principles of Basal Insulin Therapy in Type 2 Diabetes
title_full_unstemmed Current State and Principles of Basal Insulin Therapy in Type 2 Diabetes
title_short Current State and Principles of Basal Insulin Therapy in Type 2 Diabetes
title_sort current state and principles of basal insulin therapy in type 2 diabetes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827224/
https://www.ncbi.nlm.nih.gov/pubmed/35211212
http://dx.doi.org/10.14740/jocmr4660
work_keys_str_mv AT vargasuricoecheahernando currentstateandprinciplesofbasalinsulintherapyintype2diabetes